Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study

[Introduction] Acromegaly is an uncommon disease with important comorbidity and economic cost. Although the pharmacological cost of second-line treatment for refractory acromegaly has been theoretically analyzed, real-life studies are needed.

Detalles Bibliográficos
Autores: Venegas Moreno, Eva, Jiménez-Sánchez, Andrés, Remón-Ruiz, Pablo, Dios, Elena, Perea Cortés, Jaime, Hernández-Reina, Celia, Cano, David A., Soto Moreno, Alfonso
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/391046
Acceso en línea:http://hdl.handle.net/10261/391046
Access Level:acceso abierto
Palabra clave:Acromegaly
Cost analysis
Pasireotide
Pegvisomant
Radiotherapy
Descripción
Sumario:[Introduction] Acromegaly is an uncommon disease with important comorbidity and economic cost. Although the pharmacological cost of second-line treatment for refractory acromegaly has been theoretically analyzed, real-life studies are needed.

Similares en LA Referencia